On May 15, 2023, Sarepta Therapeutics experienced a significant surge in their shares by almost 24%. This was due to a panel of external experts voting 8-6 in favor of accelerated approval of the company’s DMD gene therapy for treating patients with Duchenne muscular dystrophy (DMD). The final decision from the FDA is expected later this month, and if approved, SRP-9001 would be the first gene therapy specifically designed to treat DMD.
Tazeen Ahmad, an analyst from Bank of America, reiterated her Buy rating on Sarepta and raised her price target from $164 to $176. Ahmad anticipates a 90% likelihood of success for SRP-9001 and expects it to completely transform Sarepta’s growth and earnings profile. According to Bank of America’s projections, there will be an EPS loss of $11.41 in fiscal 2023, which will transition to a profit of $1.27 per share in fiscal 2024 and $15.15 per share in fiscal 2025. Ahmad also projects a revenue growth of 19.4% in 2023, which will ramp up to 78.5% growth in 2024.
SRPT Stock Falls 3.63% on May 15, 2023: Analyzing the Companys Ratios and Growth Potential
On May 15, 2023, SRPT stock opened at $151.50, down 3.63% from the previous day’s close of $157.16. The day’s range was between $147.17 and $159.70, with a volume of 373,100 shares traded. The market cap of SRPT was $11.1 billion.
SRPT is a health technology company in the pharmaceuticals: major industry. The earnings growth for this year was -17.43%, and the earnings growth for the next five years is expected to be +67.30%. The P/E ratio for SRPT is not available, as the company has negative earnings.
The price/sales ratio for SRPT is 12.16, and the price/book ratio is 27.32. These ratios suggest that the stock may be overvalued. However, investors should consider other factors such as the company’s growth potential and competitive landscape before making investment decisions.
SRPT’s next reporting date is August 2, 2023, and the EPS forecast for this quarter is -$1.75. The net profit margin for SRPT was -75.40%.
In summary, SRPT’s stock performance on May 15, 2023, was down from the previous day’s close, with the stock opening at $151.50. Investors should consider the company’s growth potential and competitive landscape before making investment decisions.
Sarepta Therapeutics Incs Median Target Price Predicts +10.08% Increase, Analysts Recommend Buying Stock
On May 15, Sarepta Therapeutics Inc (SRPT) had a median target price of $173.00, according to 21 analysts who offered 12-month price forecasts. The high estimate was $206.00, while the low estimate was $139.00. This indicates that the median estimate represents a +10.08% increase from the last price of $157.16. The consensus among 22 polled investment analysts was to buy stock in Sarepta Therapeutics Inc. Sarepta Therapeutics Inc is expected to report earnings per share (EPS) of -$1.75 and sales of $260.5 million on August 02.
Discussion about this post